These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 37717659)

  • 41. Anti-PEG IgM production and accelerated blood clearance phenomenon after the administration of PEGylated exosomes in mice.
    Emam SE; Elsadek NE; Abu Lila AS; Takata H; Kawaguchi Y; Shimizu T; Ando H; Ishima Y; Ishida T
    J Control Release; 2021 Jun; 334():327-334. PubMed ID: 33957196
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A Maleimide-Terminally Modified PEGylated Liposome Induced the Accelerated Blood Clearance Independent of the Production of Anti-PEG IgM Antibodies.
    Ishima Y; Yamazaki N; Chuang VTG; Shimizu T; Ando H; Ishida T
    Biol Pharm Bull; 2022; 45(10):1518-1524. PubMed ID: 36184510
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Impact of anti-PEG IgM antibodies on the pharmacokinetics of pegylated asparaginase preparations in mice.
    Poppenborg SM; Wittmann J; Walther W; Brandenburg G; Krähmer R; Baumgart J; Leenders F
    Eur J Pharm Sci; 2016 Aug; 91():122-30. PubMed ID: 27292820
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Elucidation of accelerated blood clearance phenomenon caused by repeat injection of PEGylated nanocarriers].
    Koide H; Asai T; Hatanaka K; Shimizu K; Yokoyama M; Ishida T; Kiwada H; Oku N
    Yakugaku Zasshi; 2009 Dec; 129(12):1445-51. PubMed ID: 19952519
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Peritoneal B Cells Play a Role in the Production of Anti-polyethylene Glycol (PEG) IgM against Intravenously Injected siRNA-PEGylated Liposome Complexes.
    Shimizu T; Lila ASA; Kitayama Y; Abe R; Takata H; Ando H; Ishima Y; Ishida T
    Biol Pharm Bull; 2024; 47(2):469-477. PubMed ID: 38383000
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Factors affecting the accelerated blood clearance of polyethylene glycol-liposomes upon repeated injection.
    Laverman P; Carstens MG; Boerman OC; Dams ET; Oyen WJ; van Rooijen N; Corstens FH; Storm G
    J Pharmacol Exp Ther; 2001 Aug; 298(2):607-12. PubMed ID: 11454922
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluating the Accelerated Blood Clearance Phenomenon of PEGylated Nanoemulsions in Rats by Intraperitoneal Administration.
    Su Y; Liu M; Liang K; Liu X; Song Y; Deng Y
    AAPS PharmSciTech; 2018 Oct; 19(7):3210-3218. PubMed ID: 30187444
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comprehensive analysis of PEGylated liposome-associated proteins relating to the accelerated blood clearance phenomenon by combination with shotgun analysis and conventional methods.
    Kawanishi M; Hashimoto Y; Shimizu T; Sagawa I; Ishida T; Kiwada H
    Biotechnol Appl Biochem; 2015; 62(4):547-55. PubMed ID: 25196743
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Optimized Enzyme-Linked Immunosorbent Assay for Anti-PEG Antibody Detection in Healthy Donors and Patients Treated with PEGylated Liposomal Doxorubicin.
    Li Y; Ettah U; Jacques S; Gaikwad H; Monte A; Dylla L; Guntupalli S; Moghimi SM; Simberg D
    Mol Pharm; 2024 Jun; 21(6):3053-3060. PubMed ID: 38743264
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pre-treatment with high molecular weight free PEG effectively suppresses anti-PEG antibody induction by PEG-liposomes in mice.
    McSweeney MD; Shen L; DeWalle AC; Joiner JB; Ciociola EC; Raghuwanshi D; Macauley MS; Lai SK
    J Control Release; 2021 Jan; 329():774-781. PubMed ID: 33038448
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A minimal physiologically based pharmacokinetic model that predicts anti-PEG IgG-mediated clearance of PEGylated drugs in human and mouse.
    McSweeney MD; Wessler T; Price LSL; Ciociola EC; Herity LB; Piscitelli JA; Zamboni WC; Forest MG; Cao Y; Lai SK
    J Control Release; 2018 Aug; 284():171-178. PubMed ID: 29879519
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Accelerated blood clearance of PEGylated PLGA nanoparticles following repeated injections: effects of polymer dose, PEG coating, and encapsulated anticancer drug.
    Saadati R; Dadashzadeh S; Abbasian Z; Soleimanjahi H
    Pharm Res; 2013 Apr; 30(4):985-95. PubMed ID: 23184228
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Recent advances in the study of accelerated blood clearance phenomenon of PEGylated liposomes].
    Xu H; Wang KQ; Huang WW; Deng YH; Chen DW
    Yao Xue Xue Bao; 2010 Jun; 45(6):677-83. PubMed ID: 20939173
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ganglioside inserted into PEGylated liposome attenuates anti-PEG immunity.
    Mima Y; Abu Lila AS; Shimizu T; Ukawa M; Ando H; Kurata Y; Ishida T
    J Control Release; 2017 Mar; 250():20-26. PubMed ID: 28179196
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Activation of CYP3A by Accelerated Blood Clearance Phenomenon Potentiates the Hepatocellular Carcinoma-Targeting Therapeutic Effects of PEGylated Anticancer Prodrug Liposomes.
    Zhang X; Pan J; Ye X; Chen Y; Wang L; Meng X; Chen W; Wang F
    Drug Metab Dispos; 2023 Dec; 51(12):1651-1662. PubMed ID: 37775330
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Intravenous administration of polyethylene glycol-coated (PEGylated) proteins and PEGylated adenovirus elicits an anti-PEG immunoglobulin M response.
    Shimizu T; Ichihara M; Yoshioka Y; Ishida T; Nakagawa S; Kiwada H
    Biol Pharm Bull; 2012; 35(8):1336-42. PubMed ID: 22863934
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Influence of phospholipid types and animal models on the accelerated blood clearance phenomenon of PEGylated liposomes upon repeated injection.
    Xu H; Ye F; Hu M; Yin P; Zhang W; Li Y; Yu X; Deng Y
    Drug Deliv; 2015; 22(5):598-607. PubMed ID: 24524364
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pegfilgrastim (PEG-G-CSF) induces anti-PEG IgM in a dose dependent manner and causes the accelerated blood clearance (ABC) phenomenon upon repeated administration in mice.
    Elsadek NE; Lila ASA; Emam SE; Shimizu T; Takata H; Ando H; Ishima Y; Ishida T
    Eur J Pharm Biopharm; 2020 Jul; 152():56-62. PubMed ID: 32376372
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Application of polyglycerol coating to plasmid DNA lipoplex for the evasion of the accelerated blood clearance phenomenon in nucleic acid delivery.
    Abu Lila AS; Uehara Y; Ishida T; Kiwada H
    J Pharm Sci; 2014 Feb; 103(2):557-66. PubMed ID: 24347396
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Anti-PEG antibodies compromise the integrity of PEGylated lipid-based nanoparticles via complement.
    Estapé Senti M; de Jongh CA; Dijkxhoorn K; Verhoef JJF; Szebeni J; Storm G; Hack CE; Schiffelers RM; Fens MH; Boross P
    J Control Release; 2022 Jan; 341():475-486. PubMed ID: 34890719
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.